POINT BIOPHARMA GLOBAL INC. Operating Income
POINT BIOPHARMA GLOBAL INC. reported Operating Income of -$29.63 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2023-11-13
- POINT BIOPHARMA GLOBAL INC. operating income (loss) for the quarter ending 2023-09-30 was -$29.63M.
- POINT BIOPHARMA GLOBAL INC. operating income (loss) for the quarter ending 2023-06-30 was -$31.50M.
- POINT BIOPHARMA GLOBAL INC. operating income (loss) for the quarter ending 2023-03-31 was -$22.46M.
- POINT BIOPHARMA GLOBAL INC. operating income (loss) for the quarter ending 2022-12-31 was $191.36M.
- POINT BIOPHARMA GLOBAL INC. operating income (loss) for fiscal 2022 was $125.52M.
- POINT BIOPHARMA GLOBAL INC. operating income (loss) for fiscal 2021 was -$45.51M.
- POINT BIOPHARMA GLOBAL INC. operating income (loss) for fiscal 2020 was -$13.11M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|
| 2023-09-30 | -$29.63M 10-Q · filed 2023-11-13 | -$61.13M derived: sum of 2 quarters · filed 2023-11-13 | -$83.59M 10-Q · filed 2023-11-13 | $107.77M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2023-06-30 | -$31.50M 10-Q · filed 2023-08-14 | -$53.96M 10-Q · filed 2023-08-14 | $137.40M derived: sum of 3 quarters · filed 2023-08-14 | $112.76M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2023-03-31 | -$22.46M 10-Q · filed 2023-05-15 | $168.90M derived: sum of 2 quarters · filed 2023-05-15 | $144.26M derived: sum of 3 quarters · filed 2023-11-13 | $119.37M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-12-31 | $191.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $166.73M derived: sum of 2 quarters · filed 2023-11-13 | $141.83M derived: sum of 3 quarters · filed 2023-11-13 | $125.52M 10-K · filed 2023-03-27 | |
| 2022-09-30 | -$24.64M 10-Q · filed 2023-11-13 | -$49.53M derived: sum of 2 quarters · filed 2023-11-13 | -$65.84M 10-Q · filed 2023-11-13 | -$79.94M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$24.89M 10-Q · filed 2023-08-14 | -$41.20M 10-Q · filed 2023-08-14 | -$55.30M derived: sum of 3 quarters · filed 2023-08-14 | -$72.33M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$16.31M 10-Q · filed 2023-05-15 | -$30.40M derived: sum of 2 quarters · filed 2023-05-15 | -$47.44M derived: sum of 3 quarters · filed 2023-05-15 | -$56.09M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$14.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$31.13M derived: sum of 2 quarters · filed 2023-03-27 | -$39.78M derived: sum of 3 quarters · filed 2023-03-27 | -$45.51M 10-K · filed 2023-03-27 | |
| 2021-09-30 | -$17.03M 10-Q · filed 2022-11-14 | -$25.68M derived: sum of 2 quarters · filed 2022-11-14 | -$31.42M 10-Q · filed 2022-11-14 | -$31.55M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$8.65M 10-Q · filed 2022-08-12 | -$14.38M 10-Q · filed 2022-08-12 | -$14.51M derived: sum of 3 quarters · filed 2022-08-12 | -$17.59M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | -$5.73M 10-Q · filed 2022-05-13 | -$1.40M 10-Q · filed 2021-04-29 | -$5.86M derived: sum of 2 quarters · filed 2022-05-13 | -$8.94M derived: sum of 3 quarters · filed 2022-05-13 | -$12.17M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$130.23K derived: 10-K 9 month − 10-Q 6 month · filed 2021-03-04 | -$3.21M derived: sum of 2 quarters · filed 2021-11-12 | -$317.91K 10-K · filed 2021-03-04 | -$13.11M 10-K · filed 2022-03-25 | |
| 2020-09-30 | -$3.08M 10-Q · filed 2021-11-12 | -$168.31K 10-Q · filed 2020-11-02 | -$187.68K 10-Q · filed 2020-11-02 | -$7.71M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$3.23M 10-Q · filed 2021-08-13 | -$4.64M 10-Q · filed 2021-08-13 |